Buy or sell Biosplice Therapeutics stock pre IPO via an EquityZen fund
EquityZen is a marketplace for shares of proven pre IPO tech companies
Biosplice Therapeutics Stock
Tissue-Level Regeneration
About Biosplice Therapeutics Stock
Samumed is in the medical research and development for tissue-level regeneration. With their platform's origins in small molecule-based Wnt pathway modulation, they develop therapeutics to address a range of degenerative diseases, regenerative medicine, and oncology. Samumed adopted a fresh operating philosophy from the beginning — one based on a goal of building a broad technology platform aimed at modulating regenerative pathways to improve patient health.
Investors
aMoon Fund
Esas Ventures
Eventide Asset Management
Polar Light Ventures
Sands Capital Management
Starling group
Symbiosis Group
Vickers Venture Partners
Funding History
| February 2021 | $60.0M |
|---|---|
| March 2021 | $60.0M |
Management
Chief Executive Officer
Samikoglu Cevdet
Chief Financial Officer
Horsley Erich
Press
Globe Newswire - Jun, 1 2020
xconomy - Jun, 1 2020
Intrado - Oct, 2 2019
Intrado - Jul, 18 2019
Intrado - May, 2 2019
Globe Newswire - Feb, 28 2019
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
